Pfizer to settle Bextra, Celebrex claims for $894M
Pharma Compliance Alert, October 22, 2008
Pfizer has agreed in principle to pay $894 million to settle all lawsuits related to its non-steroidal anti-inflammatory drugs Bextra and Celebrex, according to a company release.
The settlement covers more than 90% of the personal injury lawsuits filed by patients who claim the drugs caused a heart attack, stroke, or other injury. The settlement also resolves payer class action consumer fraud cases involving Bextra and Celebrex in which plaintiffs allege economic loss relating to the promotion of these medications.
Pfizer also reached an agreement to settle claims by 33 states and the District of Columbia relating to alleged marketing practices for Bextra.
Comments
0 comments on “Pfizer to settle Bextra, Celebrex claims for $894M ”
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- COT basics to best
- Searched
